Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy

[1]  E. Burks,et al.  Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. , 2020, Blood advances.

[2]  D. Dingli,et al.  Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis , 2020, Blood Cancer Journal.

[3]  P. Hawkins,et al.  A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. , 2019, Blood.

[4]  D. Dingli,et al.  Revisiting complete response in light chain amyloidosis , 2019, Leukemia.

[5]  C. Varga,et al.  In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival , 2019, Blood.

[6]  K. Thoren,et al.  MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[7]  L. Ramanathan,et al.  Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay. , 2019, The journal of applied laboratory medicine.

[8]  P. Milani,et al.  What does minimal residual disease mean in AL amyloidosis? , 2018, Expert Opinion on Orphan Drugs.

[9]  A. Dispenzieri,et al.  Systemic immunoglobulin light chain amyloidosis , 2018, Nature Reviews Disease Primers.

[10]  D. Dingli,et al.  Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio , 2018, Leukemia.

[11]  D. Dingli,et al.  Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains , 2018, Leukemia.

[12]  H. Goldschmidt,et al.  AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. , 2017, Blood.

[13]  P. Milani,et al.  The utility of MASS‐FIX to detect and monitor monoclonal proteins in the clinic , 2017, American journal of hematology.

[14]  D. Dingli,et al.  The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. , 2017, Blood.

[15]  A. Foli,et al.  Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response , 2016 .

[16]  T. Plesner,et al.  Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference , 2016, Clinical chemistry and laboratory medicine.

[17]  A. Foli,et al.  Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. , 2015, Blood.

[18]  A. Foli,et al.  A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. , 2014, Blood.

[19]  M. Dimopoulos,et al.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.